Author:
Verma Amit,Pandey Vikas,Yuan Nanxue,Sherry Catherine,Humphrey Taylor,James Christopher,Young Tynan,Williams John C,Intes Xavier,Barroso Margarida
Abstract
Our study demonstrates the utility of macroscopic fluorescence lifetime (MFLI) fluorescence resonance energy transfer (FRET) imaging to non-invasively monitor targeted drug tumor delivery via quantitative assessment of meditope-labeled antibody-receptor engagement in intact, live tumor xenografts.